Overexpression of BCL-XLunderlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1699-1706

  Li, Xiao Ying ^a,b   Marani, Michela ^a,b   Mannucci, Roberta ^c   Kinsey, Berma ^a,b   Andriani, Francesca ^a   Nicoletti, Ildo ^c   Denner, Larry ^d   Marcelli, Marco ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ANION CHANNEL; BUTYRIC ACID; CASPASE 3; CASPASE 9; CYTOCHROME C; DNA FRAGMENT; GENISTEIN; GREEN FLUORESCENT PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLIGONUCLEOTIDE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL XL; PROTEIN TYROSINE KINASE INHIBITOR; STAUROSPORINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME DEGRADATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CARRIER PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENISTEIN; HUMANS; MALE; MITOCHONDRIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAUROSPORINE; SUBCELLULAR FRACTIONS; TUMOR CELLS, CULTURED;

EID: 0035866339     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Death receptors: Signaling and modulation
2. Mitochondria and apoptosis
3. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β
4. Caspases: Enemies within
5. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for the treatment of prostate cancer
6. Regulated targeting of BAX to mitochondria
7. Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis
8. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-xl
9. Akt phosphorylation of BAD couples survival signals to the cell- intrinsic death machinery
10. Interteukin-3-induced phosphorylation of BAD through the protein kinase Akt
11. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
12. Regulation of cell death protease caspase-9 by phosphorylation
13. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors
14. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-ΚB that blocks TNFα-induced apoptosis
15. NF-ΚB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c- IAP2 to suppress caspase-8 activation
16. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome C release during apoptosis
17. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane
18. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis
19. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death
20. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome C
21. Smac a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition
22. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
23. Molecular characterization of mitochondrial apoptosis-inducing factor
24. Cytochrome C and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
25. Relationship between metastatic ability and H-ras oncogene expression in rat mammary cancer cells transfected with the v-H-ras oncogene
26. Early androgen deprivation for prostate cancer?
27. Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation
28. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy
29. c-JUN N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide
30. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
31. Conformation of the Bax C-terminus regulates subcellular location and cell death
32. The LNCaP cell line - A new model for studies on human prostatic carcinoma
33. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
34. Enforced dimerization of BAX results in its translocation, mitocbondrial dysfunction, and apoptosis
35. Caspase cleaved BID targets mitochondria and is required for cytochrome C release, while BCL-XL prevents this release but not tumor necrosis factor-RI/Fas death
36. The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas
37. The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides
38. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
39. Bid, a Bcl2 interacting protein, mediates cytochrome C release from mitochondria in response to activation of cell surface death receptors
40. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
41. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome C release in isolated mitochondria
42. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis
43. Two distinct signaling pathways downstream of Janus kinase 2 play redundant roles for anti-apoptotic activity of granulocyte-macrophage colony-stimulating factor
44. Butyrrate attenuates BCL-XL expression in PC-3 cells and interacts with ionizing radiations to induce apoptosis
45. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression
46. Abrogation of mitochondrial cytochrome C release and caspase-3 activation in acquired multidrug resistance
47. Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins
48. A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas
49. Las an inhibitor of cytosolic cytochrome C accumulation in DNA damageinduced apoptosis
50. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax
51. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax
52. Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange
53. IFN-γ upregulates anti-apoptotic gene expression and inhibits apoptosis in IL-3-dependent hematopoietic cells
54. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies
55. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells
56. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
57. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage
58. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
59. Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers